Heterogeneity of PTEN and PPAR‑γ in cancer and their prognostic application to bladder cancer

Zhang, Zhouzhou; Xu, Huan; Jen, Jin; Shi, Xiaolei; Lyu, Ji Hyo; Zhu, Yasheng; Yu, Hongqi; Wang, Fubo

doi:10.3892/etm.2019.7879

Cited by 13 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This compound ligates to the transcription factor peroxisome proliferator-activator receptor gamma (PPARγ), which regulation has been found to regulate genes with anti-proliferative and anti-inflammatory effects and play a protective role against tumor development [154,155]. Some PPARγ agonists, including 15-keto-PGE 2 and thiazolidinediones, have been proposed as potential pharmacological therapeutical drugs in cancer [156][157][158][159]. However, it is still unclear whether PPARs act as bona fide tumor suppressor or as an oncogene, and more studies are needed to understand their role in cancer for the development of efficient and safe chemotherapeutic agents targeting these molecules [154].…”

Section: Coxsmentioning

confidence: 99%

Targeting Lipid Peroxidation for Cancer Treatment

et al. 2020

View full text Add to dashboard Cite

Cancer is one of the highest prevalent diseases in humans. The chances of surviving cancer and its prognosis are very dependent on the affected tissue, body location, and stage at which the disease is diagnosed. Researchers and pharmaceutical companies worldwide are pursuing many attempts to look for compounds to treat this malignancy. Most of the current strategies to fight cancer implicate the use of compounds acting on DNA damage checkpoints, non-receptor tyrosine kinases activities, regulators of the hedgehog signaling pathways, and metabolic adaptations placed in cancer. In the last decade, the finding of a lipid peroxidation increase linked to 15-lipoxygenases isoform 1 (15-LOX-1) activity stimulation has been found in specific successful treatments against cancer. This discovery contrasts with the production of other lipid oxidation signatures generated by stimulation of other lipoxygenases such as 5-LOX and 12-LOX, and cyclooxygenase (COX-2) activities, which have been suggested as cancer biomarkers and which inhibitors present anti-tumoral and antiproliferative activities. These findings support the previously proposed role of lipid hydroperoxides and their metabolites as cancer cell mediators. Depletion or promotion of lipid peroxidation is generally related to a specific production source associated with a cancer stage or tissue in which cancer originates. This review highlights the potential therapeutical use of chemical derivatives to stimulate or block specific cellular routes to generate lipid hydroperoxides to treat this disease.

show abstract

Section: Coxsmentioning

confidence: 99%

Targeting Lipid Peroxidation for Cancer Treatment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…At present, it is believed that the peroxisome pathway mainly inhibits tumor proliferation, metastasis, and invasion by activating the expression of PTEN, c-myc, and p27 [33,34]. The peroxisome pathway has also been proved to be closely related to the occurrence and development of bladder cancer, and its expression is significantly increased in bladder cancer; moreover, its expression is higher in high-grade and invasive bladder cancer than in low-grade and superficial tumors [35]. Base excision repair plays a key role in maintaining genome stability, integrity, and preventing carcinogenesis, and DNA destruction may lead to gene rearrangement, translocation, amplification, and deletion [36].…”

Section: Discussionmentioning

confidence: 99%

DNA methylation-based classification and identification of bladder cancer prognosis-associated subgroups

et al. 2020

View full text Add to dashboard Cite

Background: Bladder cancer (BCA) is the most common urinary tumor, but its pathogenesis is unclear, and the associated treatment strategy has rarely been updated. In recent years, a deeper understanding of tumor epigenetics has been gained, providing new opportunities for cancer detection and treatment. Methods: We identified prognostic methylation sites based on DNA methylation profiles of BCA in the TCGA database and constructed a specific prognostic subgroup. Results: Based on the consistent clustering of 402 CpGs, we identified seven subgroups that had a significant association with survival. The difference in DNA methylation levels was related to T stage, N stage, M stage, grade, sex, age, stage and prognosis. Finally, the prediction model was constructed using a Cox regression model and verified using the test dataset; the prognosis was consistent with that of the training set. Conclusions: The classification based on DNA methylation is closely related to the clinicopathological characteristics of BCA and determines the prognostic value of each epigenetic subtype. Therefore, our findings provide a basis for the development of DNA methylation subtype-specific therapeutic strategies for human bladder cancer.

show abstract

“…At present, it is believed that the peroxisome pathway mainly inhibits tumor proliferation, metastasis, and invasion by activating the expression of PTEN, c-myc, and p27 [33,34]. The peroxisome pathway has also been proved to be closely related to the occurrence and development of bladder cancer, and its expression is signi cantly increased in bladder cancer; moreover, its expression is higher in high-grade and invasive bladder cancer than in low-grade and super cial tumors [35]. Base excision repair plays a key role in maintaining genome stability, integrity, and preventing carcinogenesis, and DNA destruction may lead to gene rearrangement, translocation, ampli cation, and deletion [36].…”

Section: Discussionmentioning

confidence: 99%

DNA methylation-based classification and identification of bladder cancer prognosis-associated subgroups

Tian

Meng

Long

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Bladder cancer (BCA) is the most common urinary tumor, but its pathogenesis is unclear, and the associated treatment strategy has rarely been updated. In recent years, a deeper understanding of tumor epigenetics has been gained, providing new opportunities for cancer detection and treatment.Methods: We identified prognostic methylation sites based on DNA methylation profiles of BCA in the TCGA database and constructed a specific prognostic subgroup. Results: Based on the consistent clustering of 402 CpGs, we identified seven subgroups that had a significant association with survival. The difference in DNA methylation levels was related to T stage, N stage, M stage, grade, sex, age, stage and prognosis. Finally, the prediction model was constructed using a Cox regression model and verified using the test dataset; the prognosis was consistent with that of the training set. Conclusions: The classification based on DNA methylation is closely related to the clinicopathological characteristics of BCA and determines the prognostic value of each epigenetic subtype. Therefore, our findings provide a basis for the development of DNA methylation subtype-specific therapeutic strategies for human bladder cancer.

show abstract

Heterogeneity of PTEN and PPAR‑γ in cancer and their prognostic application to bladder cancer

Cited by 13 publications

References 26 publications

Targeting Lipid Peroxidation for Cancer Treatment

Targeting Lipid Peroxidation for Cancer Treatment

DNA methylation-based classification and identification of bladder cancer prognosis-associated subgroups

DNA methylation-based classification and identification of bladder cancer prognosis-associated subgroups

Contact Info

Product

Resources

About